As we previously reported, the U.S. Department of Justice (“DOJ”) filed a lawsuit under the Anti-Kickback Statute against Regeneron Pharmaceuticals in the District of Massachusetts regarding Regeneron ...
The Department of Justice on Wednesday accused drug maker Regeneron Pharmaceuticals Inc. of fraudulent practices related the pricing of its blockbuster vision-impairment drug Eylea, boosting its sales ...
The U.S. Department of Justice on Wednesday accused Regeneron of defrauding Medicare by knowingly inflating the average sales price for its top-selling eye drug Eylea. In a lawsuit filed in U.S.
BOSTON, April 10 (Reuters) - The U.S. Justice Department on Wednesday accused Regeneron Pharmaceuticals (REGN.O), opens new tab of manipulating Medicare's drug-pricing process by inflating the average ...
Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals (REGN.O), opens new tab on Thursday reported weaker-than-expected quarterly sales of the higher dose version of its blockbuster eye disease ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results